Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 100.0% in October

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,720,000 shares, an increase of 100.0% from the September 30th total of 1,860,000 shares. Approximately 17.6% of the company’s shares are sold short. Based on an average daily trading volume, of 4,310,000 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a report on Thursday, October 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $20.75.

Insider Transactions at Tempest Therapeutics

In other news, major shareholder Versant Venture Capital Vi, L. sold 387,999 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $1.10, for a total value of $426,798.90. Following the transaction, the insider now owns 209,941 shares in the company, valued at approximately $230,935.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.27% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,084 shares of the company’s stock, valued at approximately $55,000. Dimensional Fund Advisors LP owned approximately 0.11% of Tempest Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Trading Up 0.9 %

Shares of TPST traded up $0.01 during trading hours on Monday, reaching $1.10. 3,505,320 shares of the company traded hands, compared to its average volume of 2,036,458. Tempest Therapeutics has a 12 month low of $0.92 and a 12 month high of $6.00. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12. The company’s fifty day moving average price is $1.29 and its two-hundred day moving average price is $2.16. The company has a market capitalization of $24.44 million, a price-to-earnings ratio of -0.64 and a beta of -1.86.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.05. Equities research analysts predict that Tempest Therapeutics will post -1.5 earnings per share for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.